Investigational drug · Phase 2
ATSN-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Leber Congenital Amaurosis, LCA, LCA1.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ATSN-101"
First trial start
2019
Oct 22, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATSN-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leber Congenital Amaurosis
- LCA
- LCA1
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ATSN-101" as an intervention, largest first.
- Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2DActive, not recruiting
Atsena Therapeutics Inc.Industry
NCT03920007 · 15 participants · Start Oct 22, 2019 · Primary completion May 19, 2023
Drug: ATSN-101; ATSN-101 Diluent Solution and 4 more · For: Leber Congenital Amaurosis; LCA; LCA1
Sites: Portland, Oregon; Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Leber Congenital Amaurosis
- AAV2-hRPE65v2voretigene neparvovec-rzylPhase 32 trials
Roche (Genentech) · Leber Congenital Amaurosis, Inherited Retinal Dystrophy Due to RPE65 Mutations
- sepofarsenQR-110Phase 32 trials
Laboratoires Thea · Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis
- OCU400Phase 21 trial
Ocugen · Retinitis Pigmentosa, Leber Congenital Amaurosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.